Contact WAO | e-News Sign Up | Site Map | Home  
World Allergy Organization
WAO's mission: To be a global resource and advocate in the field of allergy, advancing excellence in clinical care through education, research and training as a world-wide alliance of allergy and clinical immunology societies.

Medical Journal Reviews

June 2015

Articles are selected for their importance to clinicians who care for patients with asthma and allergic/immunologic diseases by Juan Carlos Ivancevich, MD, WAO Web Editor-in-Chief, and John J. Oppenheimer, MD, FACAAI, FAAAAI, WAO Reviews Editor.

1. Analysis of airway wall structure and inflammation in preschoolers with severe recurrent wheeze.

Lezmi G, Gosset P, Deschildre A, Abou-Taam R, Mahut B, Beydon N, and de Blic J.  Airway remodeling in preschool children with severe recurrent wheeze. American Journal of Respiratory and Critical Care Medicine 2015; published online before print, 11 May. (doi:10.1164/rccm.201411-1958OC)


Editor’s comment: The authors found that in a group of preschoolers with severe wheezing episodes, markers of lung remodeling vary depending upon the patient’s age.  Interestingly, airway wall structural changes were not related to biopsy derived inflammatory cell counts. Lastly, markers of remodeling were surprisingly similar between those who wheezed as a result of multiple triggers, compared to those solely triggered by viral infection.

2. Therapeutic targeting of GATA3, an important transcription factor of the Th2 pathway, in allergic asthma.

Krug N, Hohlfeld JM, Kirsten AM, Kornmann O, Beeh KM et al. Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. The New England Journal of Medicine 2015; 372: 1987-1995. (doi:10.1056/NEJMoa141176)


Editor’s comment: In patients with allergic asthma, treatment with a novel DNA enzyme able to cleave and inactivate GATA3 messenger RNA significantly attenuated both the early and late asthmatic response after allergen provocation.

3. Identifying the EP receptor that mediates the anti-inflammatory actions of PGE2 in the lung.

Birrell MA, Maher SA, Dekkak B, Jones V, Wong S, Brook P, and Belvisi MG.  Anti-inflammatory effects of PGE2 in the lung: role of the EP4 receptor subtype. Thorax 2015; published online before print, 4 May. (doi.10/1136/throaxjnl-2014-206592)

Full Text, Free

Editor’s comment: This study identified, for the first time, through several clinically relevant models, the importance of the EP4 receptor and its associated signaling pathway as a target for a dual bronchodilator/anti-inflammatory therapy in the treatment of respiratory diseases, including asthma and chronic obstructive pulmonary disease.

4. An updated guideline on adult rhinosinusitis.

Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, Brook I, Kumar KA et al.  Clinical Practice Guideline (update): adult sinusitis executive summary. Otorhinolaryngology Head Neck Surgery 2015; 152(4): 598-609. (doi:10.1177/0194599815574247)

Full Text, Free

Editor’s comment: This article summarizes the rationale, purpose, and key action statements of the updated “Clinical Practice Guideline: Adult Sinusitis”. The 14 guideline recommendations address diagnostic accuracy and the appropriate use of ancillary tests to confirm the diagnosis and guide management (including radiography, nasal endoscopy, computed tomography, and testing for allergy and immune function) of adult rhinosinusitis. The authors also make recommendations regarding the optimal use of topical and systemic therapy.

5. Characterizing patients with chronic respiratory symptoms.

Turner AM, Tamasi L, Schleich F, Hoxha M, Horvath I, Louis R, and Barnes N. Clinically relevant subgroups in COPD and asthma. European Respiratory Review 2015; 24(136): 283-298. (doi:10.1183/16000617.000090)

Full Text, Free

Editor’s comment: In this comprehensive review, the authors develop subgroups of COPD and asthma patients whose clinical characteristics they believe have therapeutic or major prognostic implications, and they examine whether these subgroup stratifications remain constant over time. Finally, they analyze whether these subgroups are common to both asthma and COPD, focusing on how treatment might be tailored in patients where the subgroup classification is clear but the label of asthma or COPD is not.